Nine-month Figures for 2014: Sartorius Grows in Order Intake, Sales Revenue and Earnings
Group sales revenue +9.6%; order intake +10.1%; underlying EBITDA +10.7% | Strong growth in the Bioprocess Solutions Division; positive development trends for Lab Products & Services and Industrial Technologies | Forecast for the full year confirmed.
Sartorius, a leading international laboratory and pharmaceutical equipment supplier, successfully closed the first nine months of 2014 with substantial gains. Consolidated order intake grew 10.1% in constant currencies; Group sales revenue rose 9.6%. Operating Profit1) for the Group also climbed 10.7%; its respective margin after nine months was 19.6%. Based on the strong results of the past three quarters, Sartorius confirms its forecast for the full year of 2014, which projects currency-adjusted growth in sales of 8% to 10% and an increase in its EBITDA margin to around 20%.
“The Group and its divisions are on track to achieve our full-year targets,” said CEO Joachim Kreuzburg. “Our largest division, Bioprocess Solutions, continues to show the highest growth momentum. Besides its core product segments, the most recent acquisitions in this division have shown excellent performance. Business in Lab Products & Services has picked up, while its figures are still impacted by the phase-out of a few non-strategic product lines from its portfolio. The positive development trend of the second quarter has also continued on into the reporting period for our third division, Industrial Technologies.”
Follow Evolution Global Talent Attraction on Twitter, Facebook and LinkedIN to keep up-to-date with news and trends from the biotechnology, biosciences, medical device, IT and Intellectual Property industries.
